Status: Recruiting
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Participants needed: 310
Trial details
Phase: Phase 2Age: 18-64Biological sex: AllType: InterventionalSponsor: BioNTech SEUpdated: Mar 4, 2026Locations: 6
Eligibility criteria
Cohort 1: ≥18 to ≤45 years of age [+3]
Have had recent exposure to mpox (defined as close contact with a probable or co... [+5]